Table of Contents Table of Contents 2 Introduction 8 Multiple Myeloma (Kahler Disease) - Overview 9 Multiple Myeloma (Kahler Disease) - Therapeutics Development 10 Multiple Myeloma (Kahler Disease) - Therapeutics Assessment 55 Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development 81 Multiple Myeloma (Kahler Disease) - Drug Profiles 154 Multiple Myeloma (Kahler Disease) - Dormant Projects 1161 Multiple Myeloma (Kahler Disease) - Discontinued Products 1177 Multiple Myeloma (Kahler Disease) - Product Development Milestones 1180 Appendix 1189

List of Tables Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2017 46 Number of Products under Development by Companies, H2 2017 48 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 49 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 50 Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 51 Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 52 Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 53 Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 54 Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 55 Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 56 Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 57 Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 58 Number of Products under Development by Universities/Institutes, H2 2017 59 Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 61 Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 62 Products under Development by Companies, H2 2017 63 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 64 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 65 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 66 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 67 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 68 Products under Development by Companies, H2 2017 (Contd..6), H2 2017 69 Products under Development by Companies, H2 2017 (Contd..7), H2 2017 70 Products under Development by Companies, H2 2017 (Contd..8), H2 2017 71 Products under Development by Companies, H2 2017 (Contd..9), H2 2017 72 Products under Development by Companies, H2 2017 (Contd..10), H2 2017 73 Products under Development by Companies, H2 2017 (Contd..11), H2 2017 74 Products under Development by Companies, H2 2017 (Contd..12), H2 2017 75 Products under Development by Companies, H2 2017 (Contd..13), H2 2017 76 Products under Development by Companies, H2 2017 (Contd..14), H2 2017 77 Products under Development by Companies, H2 2017 (Contd..15), H2 2017 78 Products under Development by Companies, H2 2017 (Contd..16), H2 2017 79 Products under Development by Companies, H2 2017 (Contd..17), H2 2017 80 Products under Development by Companies, H2 2017 (Contd..18), H2 2017 81 Products under Development by Companies, H2 2017 (Contd..19), H2 2017 82 Products under Development by Companies, H2 2017 (Contd..20), H2 2017 83 Products under Development by Companies, H2 2017 (Contd..21), H2 2017 84 Products under Development by Companies, H2 2017 (Contd..22), H2 2017 85 Products under Development by Companies, H2 2017 (Contd..23), H2 2017 86 Products under Development by Universities/Institutes, H2 2017 87 Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 88 Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 89 Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 90 Number of Products by Stage and Target, H2 2017 92 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 93 Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 94 Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 95 Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 96 Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 97 Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 98 Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 99 Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017 100 Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017 101 Number of Products by Stage and Mechanism of Action, H2 2017 103 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 104 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 105 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 106 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 107 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 108 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 109 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 110 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017 111 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017 112 Number of Products by Stage and Route of Administration, H2 2017 114 Number of Products by Stage and Molecule Type, H2 2017 116 Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2017 117 Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2017 118 Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H2 2017 118 Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2017 119 Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2017 119 Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2017 120 Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2017 120 Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2017 121 Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2017 121 Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H2 2017 121 Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H2 2017 122 Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2017 123 Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H2 2017 123 Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2017 124 Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics Inc, H2 2017 124 Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H2 2017 125 Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H2 2017 125 Multiple Myeloma (Kahler Disease) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 125 Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc, H2 2017 126 Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals Inc, H2 2017 126 Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2017 127 Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2017 127 Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 128 Multiple Myeloma (Kahler Disease) - Pipeline by Autolus Ltd, H2 2017 128 Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2017 129 Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017 129 Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017 130 Multiple Myeloma (Kahler Disease) - Pipeline by Biomunex Pharmaceuticals, H2 2017 130 Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2017 131 Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H2 2017 131 Multiple Myeloma (Kahler Disease) - Pipeline by Boehringer Ingelheim GmbH, H2 2017 132 Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2017 132 Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Co, H2 2017 133 Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H2 2017 133 Multiple Myeloma (Kahler Disease) - Pipeline by CanBas Co Ltd, H2 2017 134 Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2017 135 Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2017 135 Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H2 2017 136 Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H2 2017 136 Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H2 2017 137 Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2017 137 Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2017 138 Multiple Myeloma (Kahler Disease) - Pipeline by Cellular Biomedicine Group Inc, H2 2017 138 Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2017 139 Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 139 Multiple Myeloma (Kahler Disease) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017 140 Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2017 140 Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 141 Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 141 Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2017 142 Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Co, H2 2017 142 Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2017 142 Multiple Myeloma (Kahler Disease) - Pipeline by eTheRNA Immunotherapies NV, H2 2017 143 Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H2 2017 143 Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 144 Multiple Myeloma (Kahler Disease) - Pipeline by Five Prime Therapeutics Inc, H2 2017 144 Multiple Myeloma (Kahler Disease) - Pipeline by Galileo Research srl, H2 2017 145 Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H2 2017 145 Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H2 2017 146 Multiple Myeloma (Kahler Disease) - Pipeline by Genentech Inc, H2 2017 146 Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2017 147 Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 147 Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H2 2017 148 Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H2 2017 148 Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H2 2017 148 Multiple Myeloma (Kahler Disease) - Pipeline by GT Biopharma Inc, H2 2017 149 Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H2 2017 149 Multiple Myeloma (Kahler Disease) - Pipeline by HitGen LTD, H2 2017 150 Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2017 150 Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene Inc, H2 2017 150 Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2017 151 Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2017 152 Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2017 152 Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2017 153 Multiple Myeloma (Kahler Disease) - Pipeline by Istesso Ltd, H2 2017 153 Multiple Myeloma (Kahler Disease) - Pipeline by Janpix Inc, H2 2017 153 Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals LLC, H2 2017 154 Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2017 155 Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2017 155 Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2017 156 Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H2 2017 156 Multiple Myeloma (Kahler Disease) - Pipeline by Karus Therapeutics Ltd, H2 2017 157 Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2017 157 Multiple Myeloma (Kahler Disease) - Pipeline by Kite Pharma Inc, H2 2017 158 Multiple Myeloma (Kahler Disease) - Pipeline by Klyss Biotech Inc, H2 2017 158 Multiple Myeloma (Kahler Disease) - Pipeline by Leadiant Biosciences Inc, H2 2017 159 Multiple Myeloma (Kahler Disease) - Pipeline by Les Laboratoires Servier SAS, H2 2017 159 Multiple Myeloma (Kahler Disease) - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 159 Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2017 160 Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune LLC, H2 2017 160 Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2017 161 Multiple Myeloma (Kahler Disease) - Pipeline by Midatech Pharma US Inc, H2 2017 161 Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 162 Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2017 162 Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2017 163 Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2017 163 Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2017 164 Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2017 164 Multiple Myeloma (Kahler Disease) - Pipeline by NantKwest Inc, H2 2017 165 Multiple Myeloma (Kahler Disease) - Pipeline by NBE-Therapeutics AG, H2 2017 165 Multiple Myeloma (Kahler Disease) - Pipeline by Neonc Technologies Inc, H2 2017 165 Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2017 166 Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H2 2017 166 Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2017 167 Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2017 168 Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2017 168 Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2017 169 Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2017 169 Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2017 170 Multiple Myeloma (Kahler Disease) - Pipeline by OncoTartis Inc, H2 2017 170 Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 171 Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H2 2017 171 Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2017 172 Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2017 172 Multiple Myeloma (Kahler Disease) - Pipeline by Phosplatin Therapeutics LLC, H2 2017 173 Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd, H2 2017 173 Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2017 173 Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2017 174 Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2017 174 Multiple Myeloma (Kahler Disease) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 175 Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2017 175 Multiple Myeloma (Kahler Disease) - Pipeline by Samyang Biopharmaceuticals Corp, H2 2017 176 Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2017 176 Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2017 177 Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Life Sciences Group Ltd, H2 2017 177 Multiple Myeloma (Kahler Disease) - Pipeline by Selvita SA, H2 2017 178 Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2017 178 Multiple Myeloma (Kahler Disease) - Pipeline by Shuttle Pharmaceuticals LLC, H2 2017 178 Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H2 2017 179 Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017 180 Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2017 180 Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 181 Multiple Myeloma (Kahler Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 181 Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2017 181 Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2017 182 Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 182 Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 183 Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2017 183 Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2017 184 Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2017 184 Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H2 2017 184 Multiple Myeloma (Kahler Disease) - Pipeline by TRACON Pharmaceuticals Inc, H2 2017 185 Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals Inc, H2 2017 185 Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2017 186 Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2017 186 Multiple Myeloma (Kahler Disease) - Pipeline by TTY Biopharm Company Ltd, H2 2017 187 Multiple Myeloma (Kahler Disease) - Pipeline by Unum Therapeutics Inc, H2 2017 187 Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2017 187 Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2017 188 Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H2 2017 188 Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2017 189 Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd, H2 2017 189 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 1197 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..1), H2 2017 1198 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..2), H2 2017 1199 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..3), H2 2017 1200 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..4), H2 2017 1201 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..5), H2 2017 1202 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..6), H2 2017 1203 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..7), H2 2017 1204 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..8), H2 2017 1205 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..9), H2 2017 1206 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..10), H2 2017 1207 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..11), H2 2017 1208 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..12), H2 2017 1209 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..13), H2 2017 1210 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..14), H2 2017 1211 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2017 (Contd..15), H2 2017 1212 Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2017 1213 Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2017 (Contd..1), H2 2017 1214 Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2017 (Contd..2), H2 2017 1215 List of Figures Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2017 46 Number of Products under Development by Companies, H2 2017 47 Number of Products under Development by Universities/Institutes, H2 2017 59 Number of Products by Top 10 Targets, H2 2017 91 Number of Products by Stage and Top 10 Targets, H2 2017 91 Number of Products by Top 10 Mechanism of Actions, H2 2017 102 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 102 Number of Products by Routes of Administration, H2 2017 113 Number of Products by Stage and Routes of Administration, H2 2017 113 Number of Products by Top 10 Molecule Types, H2 2017 115 Number of Products by Stage and Top 10 Molecule Types, H2 2017 115

4SC AG AbbVie Inc Acceleron Pharma Inc Actinium Pharmaceuticals Inc Active Biotech AB Aduro BioTech Inc Aeglea BioTherapeutics Inc Affimed GmbH AIMM Therapeutics BV Alissa Pharma Altor BioScience Corp Amgen Inc Anthera Pharmaceuticals Inc APIM Therapeutics AS Arno Therapeutics Inc Array BioPharma Inc Asana BioSciences LLC Aslan Pharmaceuticals Pte Ltd Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Aurigene Discovery Technologies Ltd Autolus Ltd Bayer AG Bellicum Pharmaceuticals Inc BeyondSpring Pharmaceuticals Inc Biomunex Pharmaceuticals Biotest AG bluebird bio Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Co Calithera Biosciences Inc CanBas Co Ltd Celgene Corp Cell Source Inc Cellectar Biosciences Inc Cellectis SA Cellerant Therapeutics Inc Celleron Therapeutics Ltd CellProtect Nordic Pharmaceuticals AB Cellular Biomedicine Group Inc Celyad SA Chong Kun Dang Pharmaceutical Corp Chugai Pharmaceutical Co Ltd Curis Inc Cyclacel Pharmaceuticals Inc Daiichi Sankyo Co Ltd DC Prime BV Eli Lilly and Co Enceladus Pharmaceuticals BV eTheRNA Immunotherapies NV Exelixis Inc F. Hoffmann-La Roche Ltd Five Prime Therapeutics Inc Galileo Research srl Gamida Cell Ltd Genenta Science srl Genentech Inc GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Gliknik Inc GlycoMimetics Inc GP Pharm SA GT Biopharma Inc Heidelberg Pharma GmbH HitGen LTD IGF Oncology LLC ImmunGene Inc Immunomedics Inc Incyte Corp Inflection Biosciences Ltd Inventiva Istesso Ltd Janpix Inc Jasco Pharmaceuticals LLC Johnson & Johnson Juno Therapeutics Inc JW Pharmaceutical Corp Kancera AB Karus Therapeutics Ltd Karyopharm Therapeutics Inc Kite Pharma Inc Klyss Biotech Inc Leadiant Biosciences Inc Les Laboratoires Servier SAS Madrigal Pharmaceuticals Inc. MediGene AG MedImmune LLC Merck & Co Inc Midatech Pharma US Inc Millennium Pharmaceuticals Inc MimiVax LLC Molecular Partners AG Molecular Templates Inc MolMed SpA MorphoSys AG NantKwest Inc NBE-Therapeutics AG Neonc Technologies Inc Nippon Kayaku Co Ltd Nordic Nanovector ASA Novartis AG Noxxon Pharma AG Oncodesign SA Oncolytics Biotech Inc Onconova Therapeutics Inc Oncopeptides AB OncoTartis Inc Ono Pharmaceutical Co Ltd Peptinov SAS Pfizer Inc Pharma Mar SA Phosplatin Therapeutics LLC Polyphor Ltd Prescient Therapeutics Ltd Progenra Inc RedHill Biopharma Ltd Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Samyang Biopharmaceuticals Corp Sanofi Seattle Genetics Inc Sellas Life Sciences Group Ltd Selvita SA Senhwa Biosciences Inc Shuttle Pharmaceuticals LLC Sorrento Therapeutics Inc Spectrum Pharmaceuticals Inc Stemline Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Sun Pharma Advanced Research Company Ltd Surface Oncology Inc Sutro Biopharma Inc Taiho Pharmaceutical Co Ltd Takeda Pharmaceutical Co Ltd Targazyme Inc TeneoBio Inc Terpenoid Therapeutics Inc Tiziana Life Sciences Plc TRACON Pharmaceuticals Inc Tragara Pharmaceuticals Inc Transgene Biotek Ltd Trillium Therapeutics Inc TTY Biopharm Company Ltd Unum Therapeutics Inc Vaccibody AS Vaxil Bio Therapeutics Ltd Vivolux AB Vyriad Inc XTL Biopharmaceuticals Ltd